Open Accelerator logo

Open Accelerator

Founded: 2016

Call for Women's Health Innovations

Alumni Startups

46

Successful Exits

1

Total Investments

8

About the Program

Funding Type
Description

Established in 2016 and sponsored by Zcube, Zambon Research Venture, Open Accelerator has experienced significant growth over the years. In 2024, we are launching an entirely new program aimed at accelerating companies that are pioneering breakthrough innovations in women's health. The redesigned program will accelerate businesses developing new products by leveraging Zambon Group’s expertise. We are actively seeking innovators whose solutions are reshaping the future of healthcare through the adoption of cutting-edge technologies, such as novel therapeutic approaches, medical devices, biomarkers, advanced analytics, and more. Our goal is to identify projects and startups that are revolutionizing the patient experience across the entire healthcare journey, covering aspects of healthy living, awareness and engagement, prevention, diagnosis, therapy, disease management, and follow-up care. We go beyond money: as part of the program, startups and projects will have access to the competences of our pharmaceutical group (Sales & Marketing, Clinical and Medical affairs, Regulatory, Reimbursement, etc.) and our high-level mentor network which melds science, business and investments. The Zambon Group could engage with selected startups and projects to discuss strategic collaborations and offer geographic exposure in the EU, US, Asia, and LatAm.

Founded2016

Location

Cities
Countries
Remote Program Available

Program Details

Cohorts per Year1

Key Dates

Duration2months
Start Date23 September 2024
Closed

Investment Offer

Offer€100k
Details

We provide companies with a €100,000 (or equivalent in other currencies using relevant exchange rate at the time of investment) cash investment with a SAFE instrument with post-money capped at €3,5M (giving a maximum shareholding post-SAFE/pre-new-round of about 3%) and pro-rata rights.